PURPOSE: To investigate oxygenation, perfusion, and cell proliferation in two murine colon carcinoma lines with known differences in chemotherapy sensitivity and analyze the effect of nicotinamide and carbogen on these tumor characteristics. METHODS AND MATERIALS: Mice with s.c. transplanted C38 and C26a murine colon tumors were treated with nicotinamide and carbogen and compared with control tumors. Two markers of hypoxia, CCI-103F and pimonidazole, were injected before and after treatment with nicotinamide/carbogen, respectively, allowing each tumor to serve as its own control. Hoechst33342 was used as a perfusion marker and bromodeoxyuridine (BrdUrd) as a proliferation marker. Frozen tumors were cut for multistep immunostaining and computer-controlled microscope scanning for hypoxic fractions (HF), perfused fractions (PF), vascular density, and BrdUrd-labeling index (LI). RESULTS: Microscopic observation of C38 and C26a tumors showed extensive differences in vascular architecture, distribution patterns of hypoxia, and BrdUrd-labeling. Quantitative analysis of C38 and C26a tumors showed a decrease in HF in response to all treatment modalities. For C38 tumors, the average decrease in HF in response to carbogen containing treatments was larger than to nicotinamide alone. In C26a tumors, no difference in average decrease in HF was observed between the treatments. The PF of C38 and C26a did not change in response to treatment. The LI of C38 and C26a decreased upon all treatments, which was statistically significant in the combination treatment of C38. CONCLUSIONS: The mechanism that can simultaneously explain all the observed changes in response to treatment may be the conversion of metabolism from less respiration toward more glycolysis due to increased glucose levels (Crabtree effect), although other mechanisms of actions cannot be excluded.
PURPOSE: To investigate oxygenation, perfusion, and cell proliferation in two murinecolon carcinoma lines with known differences in chemotherapy sensitivity and analyze the effect of nicotinamide and carbogen on these tumor characteristics. METHODS AND MATERIALS: Mice with s.c. transplanted C38 and C26a murinecolon tumors were treated with nicotinamide and carbogen and compared with control tumors. Two markers of hypoxia, CCI-103F and pimonidazole, were injected before and after treatment with nicotinamide/carbogen, respectively, allowing each tumor to serve as its own control. Hoechst33342 was used as a perfusion marker and bromodeoxyuridine (BrdUrd) as a proliferation marker. Frozen tumors were cut for multistep immunostaining and computer-controlled microscope scanning for hypoxic fractions (HF), perfused fractions (PF), vascular density, and BrdUrd-labeling index (LI). RESULTS: Microscopic observation of C38 and C26a tumors showed extensive differences in vascular architecture, distribution patterns of hypoxia, and BrdUrd-labeling. Quantitative analysis of C38 and C26a tumors showed a decrease in HF in response to all treatment modalities. For C38 tumors, the average decrease in HF in response to carbogen containing treatments was larger than to nicotinamide alone. In C26a tumors, no difference in average decrease in HF was observed between the treatments. The PF of C38 and C26a did not change in response to treatment. The LI of C38 and C26a decreased upon all treatments, which was statistically significant in the combination treatment of C38. CONCLUSIONS: The mechanism that can simultaneously explain all the observed changes in response to treatment may be the conversion of metabolism from less respiration toward more glycolysis due to increased glucose levels (Crabtree effect), although other mechanisms of actions cannot be excluded.
Authors: Narges K Tafreshi; Mark C Lloyd; Joshua B Proemsey; Marilyn M Bui; Jongphil Kim; Robert J Gillies; David L Morse Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Kalindi Parmar; Peter Mauch; Jo-Anne Vergilio; Robert Sackstein; Julian D Down Journal: Proc Natl Acad Sci U S A Date: 2007-03-20 Impact factor: 11.205
Authors: C E Forristal; A L Brown; F M Helwani; I G Winkler; B Nowlan; V Barbier; R J Powell; G A Engler; S M Diakiw; A C W Zannettino; S Martin; D Pattabiraman; R J D'Andrea; I D Lewis; J P Levesque Journal: Leukemia Date: 2015-04-29 Impact factor: 11.528
Authors: Hanneke W M van Laarhoven; Giulio Gambarota; Jasper Lok; Martin Lammens; Yvonne L M Kamm; Theo Wagener; Cornelis J A Punt; Albert J van der Kogel; Arend Heerschap Journal: Neoplasia Date: 2006-06 Impact factor: 5.715
Authors: Bob Hamans; Anna Catharina Navis; Alan Wright; Pieter Wesseling; Arend Heerschap; William Leenders Journal: Neuro Oncol Date: 2013-10-24 Impact factor: 12.300
Authors: James Russell; Sean Carlin; Sean A Burke; Bixiu Wen; Kwang Mo Yang; C Clifton Ling Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-15 Impact factor: 7.038
Authors: Sven De Bruycker; Christel Vangestel; Steven Staelens; Tim Van den Wyngaert; Sigrid Stroobants Journal: Contrast Media Mol Imaging Date: 2018-10-18 Impact factor: 3.161
Authors: Tineke W H Meijer; Johan Bussink; Miriam Zatovicova; Paul N Span; Jasper Lok; Claudiu T Supuran; Johannes H A M Kaanders Journal: PLoS One Date: 2014-09-16 Impact factor: 3.240
Authors: Sanne A M van Lith; Ilse Roodink; Joost J C Verhoeff; Petri I Mäkinen; Jari P Lappalainen; Seppo Ylä-Herttuala; Jos Raats; Erwin van Wijk; Ronald Roepman; Stef J Letteboer; Kiek Verrijp; William P J Leenders Journal: Oncotarget Date: 2016-11-01